Evidence map›Paper›PMID 26643548›Full record

Trial reportNeurology2016

Relationship of regional brain β-amyloid to gait speed.

Natalia Del Campo, Pierre Payoux, Adel Djilali, Julien Delrieu, Emiel O Hoogendijk, Yves Rolland, Matteo Cesari, Michael W Weiner, Sandrine Andrieu, Bruno Vellas and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 84 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 2 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03333837 nacompletednot on this mapstarted 2018, after this paper: background citation

IMOVE: Improvisational Movement for People With Memory Loss and Their Caregivers

TypeinterventionalSponsorWake Forest University Health SciencesRan2018 to 2021Enrolled104ConditionsAlzheimer's Disease (Incl Subtypes), Dementia, Mild Cognitive ImpairmentArmsDance Group, Non-Group Dance, Social Group, No Contact
NCT06713070 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Pattern of Gait Abnormality As a Predictor for Disease Progression in Dementia

TypeobservationalSponsorAssiut UniversityRan2024 to 2025Enrolled102ConditionsDementia, Gait Analysis
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Longitudinal investigation of gait and Alzheimer's disease in adults with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  20. A cognitive-motor framework for spatial navigation in aging and early-stage Alzheimer's disease.Cortex; a journal devoted to the study of the nervous system and behavior · 2025
    Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 4 countries.

Natalia Del CampoFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco. nata.delcampo@gmail.com.
Pierre PayouxFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco.
Adel DjilaliFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco.
Julien DelrieuFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco.
Emiel O HoogendijkFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco.
Yves RollandFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco.
Matteo CesariFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco.
Michael W WeinerFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco.
Sandrine AndrieuFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco.
Bruno VellasFrom Gérontopôle, Institute of Ageing (N.d.C., J.D., E.O.H., Y.R., M.C., B.V.), and the Department of Epidemiology and Public Health (S.A.), University Hospital Toulouse, France; the Department of Psychiatry (N.d.C.), University of Cambridge, UK; INSERM U825 (P.P., A.D.) and INSERM UMR 1027 (M.C., S.A., B.V.), University Toulouse III Paul Sabatier, France; Department of Epidemiology & Biostatistics (E.O.H.), EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Radiology (M.W.W.), Medicine (M.W.W.), Psychiatry (M.W.W.), and Neurology (M.W.W.), University of California, San Francisco.
MAPT/DSA Study Group
Université Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate in vivo the relationship of regional brain β-amyloid (Aβ) to gait speed in a group of elderly individuals at high risk for dementia.

methodsCross-sectional associations between brain Aβ as measured with [18F]florbetapir PET and gait speed were examined in 128 elderly participants. Subjects ranged from healthy to mildly cognitively impaired enrolled in the control arm of the multidomain intervention in the Multidomain Alzheimer Preventive Trial (MAPT). Nearly all participants presented spontaneous memory complaints. Regional [18F]florbetapir (AV45) standardized uptake volume ratios were obtained via semiautomated quantitative analysis using the cerebellum as reference region. Gait speed was measured by timing participants while they walked 4 meters. Associations were explored with linear regression, correcting for age, sex, education, body mass index (BMI), and APOE genotype.

resultsWe found a significant association between Aβ in the posterior and anterior putamen, occipital cortex, precuneus, and anterior cingulate and slow gait speed (all corrected p < 0.05). A multivariate model emphasized the locations of the posterior putamen and the precuneus. Aβ burden explained up to 9% of the variance in gait speed, and significantly improved regression models already containing demographic variables, BMI, and APOE status.

conclusionsThe present PET study confirms, in vivo, previous postmortem evidence showing an association between Alzheimer disease (AD) pathology and gait speed, and provides additional evidence on potential regional effects of brain Aβ on motor function. More research is needed to elucidate the neural mechanisms underlying these regional associations, which may involve motor and sensorimotor circuits hitherto largely neglected in the pathophysiology of AD.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBrainCross-Sectional StudiesFemaleGaitHumansMalePositron-Emission TomographyAmyloid beta-Peptides

Identifiers

PMID26643548
PMCPMC4731288
OpenAlexW2195457766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.